Medicine News and Research

RSS

Researchers convert human skin cells directly into functional neurons within four to five weeks

Human skin cells can be converted directly into functional neurons in a period of four to five weeks with the addition of just four proteins, according to a study by researchers at the Stanford University School of Medicine.

27 May 2011

Patients with body dysmorphic disorder have less brain activity in visual processing

People suffering from body dysmorphic disorder, or BDD - a severe mental illness characterized by debilitating misperceptions that one appears disfigured and ugly - process visual information abnormally, even when looking at inanimate objects, according to a new UCLA study.

27 May 2011

NHLBI stops AIM-HIGH combination clinical trial in high blood cholesterol

The National Heart, Lung, and Blood Institute of the National Institutes of Health has stopped a clinical trial studying a blood lipid treatment 18 months earlier than planned. The trial found that adding high dose, extended-release niacin to statin treatment in people with heart and vascular disease, did not reduce the risk of cardiovascular events, including heart attacks and stroke.

27 May 2011

Albert Einstein College of Medicine to help shed light on causes and treatments of type 2 diabetes

Fifty years ago, adult-onset diabetes was relatively rare, affecting less than one percent of the adult population in the United States. Today, more than 25 million Americans over the age of 20 battle the disease - an alarming 11 percent of the population.

27 May 2011

Johns Hopkins announces establishment of new institute for patient safety and quality

Recognizing the urgent need to advance the science of reducing preventable harm and improve health care quality, Johns Hopkins Medicine is announcing the establishment of the Armstrong Institute for Patient Safety and Quality, an organization whose work will benefit not only Johns Hopkins patients but those around the world.

27 May 2011

ARCA plans to expand development program for Gencaro in atrial fibrillation

ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it is planning to expand the development of Gencaro, its lead cardiovascular drug candidate, to atrial fibrillation, a disease that affects more than 2.4 million patients in the United States.

27 May 2011

Southern U.S. Stroke Belt population have greater incidence of cognitive decline

27 May 2011

Tacrolimus prevents breast cancer growth in pre-clinical studies

Tacrolimus, a drug that is commonly used to prevent organ transplantation rejection, inhibits breast cancer growth in pre-clinical studies. The finding from UNC scientists was reported in the May 26th PLoS ONE.

27 May 2011

Longer looks: Stem cells, vaccinating against addictive drugs, the GOP's budget hatchet man

Krista and Tatiana are not like most other sets of twins. They are connected at their heads, where their skulls merge under a mass of shaggy brown bangs. The girls run and play and go down their backyard slide, but whatever they do, they do together, their heads forever inclined toward each other's, their neck muscles strong and sinuous from a never-ending workout. Twins joined at the head — the medical term is craniopagus — are extremely rare.

27 May 2011

New genomics research on abnormal brain development

Local researchers are finally on the road to developing targeted treatments for serious, life-long disabilities such as autism and schizophrenia, thanks to new genomics research focusing on abnormal brain development.

27 May 2011

Abiraterone acetate effective for men with advanced prostate cancer

A drug recently approved by the Food & Drug Administration for the treatment of prostate cancer is proving to give some patients the gift of time. A new study shows abiraterone acetate extends the lives of men with the most advanced form of the disease by about four months.

27 May 2011

Neurologix presents NLX-P101 Phase 2 trial in Parkinson's disease at 10th INS World Congress

Neurologix, Inc. announced the presentation today of efficacy results through one year of follow-up in patients treated as part of the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease.

27 May 2011

Tigris Pharmaceuticals begins enrollment in AFP-464 Phase 2 trial in ER-positive breast cancer

Tigris Pharmaceuticals, Inc., today announced enrollment of its first patient in a randomized Phase 2 clinical trial of AFP-464 with or without Faslodex in estrogen receptor (ER)-positive breast cancer patients.

27 May 2011

Opinion: How universities can advance global health

"I am glad to see that U.S. research universities, too, now all seem to boast programs in global health. But claiming to have programs in global health is not the same thing as creating programs that can make a difference to populations facing poverty and ill health," Paul Farmer, chair of the Department of Global Health and Social Medicine at Harvard Medical School and founding director of Partners In Health, writes in the Harvard Crimson.

27 May 2011

Cognitive decline incidence higher in southern ‘stroke belt’

New research shows that residents of the Stroke Belt—a southern portion of the U.S. with significantly elevated stroke morality rate—also have a greater incidence of cognitive decline than other regions of the country. Researchers believe shared risk factors among members of this population are to blame. Results of this study, funded by the National Institute of Neurological Disorders and Stroke (NINDS), are published in Annals of Neurology, a journal of the American Neurological Association.

26 May 2011

Mold and ragweed allergies on the rise in the U.S.

Allergies are on the rise and it is noted that more numbers of Americans sensitive to ragweed and mold. Phoenix, Las Vegas and the Riverside-San Bernardino area are among the 30 worst affected areas with this allergy.

26 May 2011

Invida announces launch of novel atopic dermatitis symptomatic treatment

Invida Group Private Limited reaffirmed its commitment to patients in Asia Pacific by announcing the launch of a novel atopic dermatitis symptomatic treatment, Atopiclair, which will be available to patients across Asia in second half of 2011.

26 May 2011

Geisinger reports positive results with computer-assisted and NLC-driven intelligent workflow solution

Geisinger Health System, widely recognized for its implementation of innovative care models, is among the first healthcare organizations in the nation to deploy advanced technology that combines a Computer-Assisted Coding application with Natural Language Comprehension™ (NLC) in order to improve clinical documentation and coding accuracy.

26 May 2011

Pharmasset, Bristol-Myers Squibb initiate PSI-7977 plus BMS-790052 combination Phase 2a trial in HCV

Pharmasset, Inc. announced today the initiation of a Phase 2a trial investigating the combination of Pharmasset's PSI-7977, a nucleotide polymerase inhibitor, and BMS-790052, Bristol-Myers Squibb Company's NS5A replication complex inhibitor, for the treatment of chronic hepatitis C.

26 May 2011

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

Boehringer Ingelheim Pharmaceuticals, Inc. will present new phase Ib data at the 2011 American Society of Clinical Oncology annual meeting in Chicago that indicates combining its investigational therapy afatinib with cetuximab at the maximum tested dose controlled disease in all (n=22) treated epidermal growth factor receptor (EGFR)-mutation positive patients with non-small cell lung cancer who developed acquired resistance to treatment with a reversible EGFR tyrosine kinase inhibitor.

26 May 2011

Medicine News and Research

Researchers convert human skin cells directly into functional neurons within four to five weeks

Patients with body dysmorphic disorder have less brain activity in visual processing

NHLBI stops AIM-HIGH combination clinical trial in high blood cholesterol

Albert Einstein College of Medicine to help shed light on causes and treatments of type 2 diabetes

Johns Hopkins announces establishment of new institute for patient safety and quality

ARCA plans to expand development program for Gencaro in atrial fibrillation

Southern U.S. Stroke Belt population have greater incidence of cognitive decline

Tacrolimus prevents breast cancer growth in pre-clinical studies

Longer looks: Stem cells, vaccinating against addictive drugs, the GOP's budget hatchet man

New genomics research on abnormal brain development

Abiraterone acetate effective for men with advanced prostate cancer

Neurologix presents NLX-P101 Phase 2 trial in Parkinson's disease at 10th INS World Congress

Tigris Pharmaceuticals begins enrollment in AFP-464 Phase 2 trial in ER-positive breast cancer

Opinion: How universities can advance global health

Cognitive decline incidence higher in southern ‘stroke belt’

Mold and ragweed allergies on the rise in the U.S.

Invida announces launch of novel atopic dermatitis symptomatic treatment

Geisinger reports positive results with computer-assisted and NLC-driven intelligent workflow solution

Pharmasset, Bristol-Myers Squibb initiate PSI-7977 plus BMS-790052 combination Phase 2a trial in HCV

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News